| Date Filed | Type | Description |
| 10/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/22/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 5% stake in KARUNA THERAPEUTICS INC |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
SC 13G
| Capital International Investors reports a 10.3% stake in Karuna Therapeutics, Inc. |
| 05/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Karuna Therapeutics, Inc.Common Stock, par value $0.0001 per share _________ Underwriting Agreement March 21, 2023 Goldman Sachs & Co. LLCJ.P. Morgan Securities LLC Morgan Stanley & Co. LLC As representatives of the several Underwritersnamed in Schedule I hereto c/o Goldman Sachs & Co. LLC200 West StreetNew York, New York 10282",
"Registration Statement”) filed on July 2, 2020 with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended , relating to the registration of the offer by Karuna Therapeutics, Inc., a Delaware corporation of an indeterminate number of any combination of securities of the types specified therein. The Registration Statement became effective upon filing with the Commission. Reference is made to our opinion letter dated July 2, 2020 and included as Exhibit 5.1 to the Registration Statement. We are delivering this supplemental opinion letter in connection with the prospectus supplement (the “Prospectus Supplement",
"Karuna Therapeutics Announces Proposed Public Offering of Common Stock",
"Karuna Therapeutics Announces Pricing of Public Offering of Common Stock" |
|
| 03/22/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/20/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/23/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 6.9% stake in KARUNA THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in KARUNA THERAPEUTICS INC |
| 02/02/2023 |
8-K
| Quarterly results |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7% stake in KARUNA THERAPEUTICS INC |
| 01/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/06/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 09/20/2022 |
SC 13D/A
| ARCH Venture Fund IX, L.P. has filed a Schedule 13D for Karuna Therapeutics, Inc. |
| 08/12/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
|